


Supplementary Information

Supplementary Figure 1: Percentage of SARS-CoV-2 variants circulating in Thailand between 21 April 2021 and 20 September 2021.



Supplementary Table 1: Characteristics of participants in the study.

Characteristics	CV+CV (<i>n</i> = 170)	CV+CV+AZ (<i>n</i> = 210)	CV+CV+INF (<i>n</i> = 78)
Sex (<i>n</i> , %)			
female	89 (52.4%)	151 (71.9%)	58 (74.4%)
male	81 (47.6%)	59 (28.1%)	20 (25.6%)
Age in years (mean, SD)	42.3 (9.6)	40.0 (9.8)	34.2 (9.9)
Interval between 1 st and 2 nd dose (median, IQR)	23 (21–26)	21 (21–26)	23 (21–28)
Interval between 2 nd and 3 rd dose (median, IQR)	N/A	70 (61–79)	N/A

Interval between 2 nd dose and symptom onset (median, IQR)	N/A	N/A	88 (68–100)
Interval between last vaccination and blood sampling (median, IQR)	29 (27–31)	28 (20–32)	N/A
Interval between symptom onset and blood sampling (median, IQR)	N/A	N/A	34 (29–43)

CV+CV, fully vaccinated with two doses of CoronaVac; CV+CV+AZ, fully vaccinated with two doses of CoronaVac then administered a third vaccination with AZD1222; CV+CV+INF, fully vaccinated with two doses of CoronaVac followed by SARS-CoV-2 breakthrough infection; IQR, interquartile range; N/A, no data available; SD, standard deviation

Supplementary Table 2: Binding antibody levels including total anti-RBD Ig, anti-RBD IgG, and anti-S1 IgA. Neutralizing activities of sera from the three groups were measured via surrogate virus neutralization tests.

	CV+CV (n = 170)	CV+CV+AZ (n = 210)	CV+CV+INF (n = 78)
Anti-RBD-Ig			
<i>n</i>	170	210	78
GMT (95% CI)	98 (83–116)	7947 (7277–8679)	18,154 (13,506–24,402)
Anti-RBD IgG			
<i>n</i>	170	210	78
GMT (95% CI)	128 (114–144)	1492 (1367–1629)	3668 (2802–4802)
Anti-S1 IgA			
<i>n</i>	51	55	78
Median (IQR)	0.9 (0.6–1.8)	5.3 (3.9–9.0)	9.0 (8.7–9.0)
sVNT-wild type			
<i>n</i>	36	36	78
Median (IQR)	66.6 (48.9–79.4)	97.7 (97.0–97.8)	97.5 (97.3–97.6)
sVNT-B.1.1.7 (alpha)			
<i>n</i>	36	36	78
Median (IQR)	42.1 (29.0–58.3)	97.2 (94.7–97.7)	97.7 (97.3–98.0)
sVNT-B.1.351 (beta)			

<i>n</i>	36	36	78
Median (IQR)	34.8 (20.5–47.3)	92.9 (86.8–94.8)	95.6 (93.7–96.2)
sVNT-B.1.617.2 (delta)			
<i>n</i>	36	36	78
Median (IQR)	48.9 (36.1–63.4)	97.2 (95.6–97.9)	97.9 (97.7–98.0)

CI, confidence interval; CV+CV, fully vaccinated with two doses of CoronaVac; CV+CV+AZ, fully vaccinated with two doses of CoronaVac then administered a third vaccination with AZD1222; CV+CV+INF, fully vaccinated with two doses of CoronaVac followed by SARS-CoV-2 breakthrough infection; GMT, geometric mean titre; IQR, interquartile range; RBD, receptor-binding domain